Balyasny Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Balyasny Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,500	Closed	-$822K	–	2887
2025 Q4	$822K	Sell	4,500 -2,000	-31%	-$279K	﹤0.01%	2282
2025 Q3	$789K	Buy	6,500 +1,400	+27%	+$158K	﹤0.01%	2216
2025 Q2	$532K	Sell	5,100 -1,800	-26%	-$191K	﹤0.01%	2272
2025 Q1	$805K	Buy	+6,900	New	+$786K	﹤0.01%	2086
2024 Q4	–	Sell	-4,700	Closed	-$422K	–	2725
2024 Q3	$422K	Buy	+4,700	New	+$410K	﹤0.01%	2333
2023 Q3	–	Sell	-39,000	Closed	-$2.8M	–	2251
2023 Q2	$2.8M	Buy	+39,000	New	+$2.88M	0.01%	1261
2020 Q4	–	Sell	-40,000	Closed	-$2.85M	–	1319
2020 Q3	$2.85M	Buy	+40,000	New	+$3.12M	0.02%	745

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's AXSM Position: Q2 2025 in Review

Balyasny Asset Management sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 24,431 shares — an estimated $2.59M sold.

Balyasny Asset Management first reported a position in AXSM in Q1 2018 and held it in 8 quarters. The position peaked at $15.3M in Q4 2024. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

Balyasny Asset Management reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
Balyasny Asset Management sold 24,431 Axsome Therapeutics shares in Q2 2025, an estimated $2.59M.
Balyasny Asset Management first reported a position in Axsome Therapeutics in Q1 2018 and held it in 8 quarters.
Balyasny Asset Management's Axsome Therapeutics position peaked at $15.3M in Q4 2024.
348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.